Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a report issued on Sunday morning. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

CHEK stock opened at $1.41 on Friday. The stock has a market capitalization of $8.25 million, a P/E ratio of -0.47 and a beta of 0.39. Check-Cap has a fifty-two week low of $1.40 and a fifty-two week high of $4.59. The business has a 50-day moving average of $1.88 and a 200-day moving average of $2.10.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.